Keywords: Pfizer, Lipitor, Cholesterol, Caduaet, Hypertension, Ranbaxy, USA
Payers’ outlook for Pfizer’s Lipitor generic strategy not rosy; second Caduet copy launched by Ranbaxy
Article | 06 December 2011
Reimbursement Intelligence, a USA-based market-research firm, has announced how payers predict the impact of US drugs behemoth Pfizer's (NYSE: PFE) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
